Company Overview and News

1
Dr Mahathir marks 100 days as growth risks mount in Malaysia

2018-08-17 theedgemarkets
KUALA LUMPUR (Aug 17): Malaysian Prime Minister Tun Dr Mahathir Mohamad marks his 100 days in office with risks mounting against the economy.
NMR UOVEF 8604 N33 UOVEY NRSCF U11

1
Dr M marks 100 days as growth risks mount in Malaysia

2018-08-17 malaymail
KUALA LUMPUR, Aug 17 — Malaysian Prime Minister Tun Dr Mahathir Mohamad marks his 100 days in office with risks mounting against the economy.
NMR UOVEF 8604 N33 UOVEY NRSCF U11

1
Argentina boosts world’s highest rates amid Turkey contagion

2018-08-13 malaymail
BUENOS AIRES, Aug 14 — Argentina took emergency steps to stabilise its currency in the wake of an emerging-market rout caused by Turkey’s crisis, jacking up its already highest-in-the-world interest rate by 5 percentage points and announcing it will sell US$500 million (RM2.04 billion) to support the peso.
NMR 8604 N33 NRSCF

1
Soviet collapse echoes in China’s Belt and Road

2018-08-13 theedgemarkets
According to one influential view, it’s ultimately a question of investment. Great powers are the nations that best harness their economic potential to build up military strength. When they become over-extended, the splurge of spending to sustain a strategic edge leaves more productive parts of the economy starved of capital, leading to inevitable decline.
NMR 8604 N33 NRSCF

1
NMR / Nomura Holdings, Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-09 sec.gov
Form 6-K Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION
NMR

110
XRT / SPDR S&P Retail ETF - Stock Institutional Ownership and Shareholders - Fintel.io

2018-08-08 fintel.io - 1
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
BCS 83SF GLSSP 83SK 8604 MS JBK TFG XRT N33 BNS CGBBW NMR BNS GS TWMJF UBS WEED NRSCF 47MC C GSC CGC GSJ GJS ULSGF

2
Biggest rate hike in a decade on the cards for Philippines

2018-08-08 theedgemarkets
(Aug 8): The question facing policy makers in the Philippines is not whether to raise interest rates for a third time in a row, but by how much.
NMR BCS STAN 83SF 8604 83SK N33 580001 STAB NRSCF STAN STAC 2888 SCBFF 47MC

2
Biggest rate hike in a decade on the cards for the Philippines

2018-08-08 bworldonline
The question facing policy makers in the Philippines is not whether to raise interest rates for a third time in a row, but by how much.
NMR BCS STAN 83SF 8604 83SK N33 580001 STAB NRSCF STAN STAC 2888 SCBFF 47MC

2
Biggest rate hike in a decade on the cards for Philippines

2018-08-08 malaymail
MANILA, Aug 8 — The question facing policy makers in the Philippines is not whether to raise interest rates for a third time in a row, but by how much.
NMR BCS STAN 83SF 8604 83SK N33 580001 STAB NRSCF STAN STAC 2888 SCBFF 47MC

2
Biggest Rate Increase in a Decade on the Cards for Philippines - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR BCS STAN 83SF 8604 83SK N33 580001 STAB NRSCF STAN STAC 2888 SCBFF 47MC

7
Goldman Sachs Is Considering a Custody Offering for Crypto Funds - Bloomberg

2018-08-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR JBK GSC NTRSP TFG GSJ GS GLSSP 7018 8604 NTRS N33 CME NRSCF GJS

1
Asia’s new stock-market king has strong profits, BOJ support

2018-08-06 bworldonline
With Japan regaining its place as the second-biggest stock market amid growing trade tensions between the world’s two largest economies, investors expect the nation’s equities to garner more attention.
NMR 8604 N33 NRSCF 9984 SFTBF 0550 SFTBY

1
Asia's New Stock-Market King Has Strong Profits, BOJ Support - Bloomberg

2018-08-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR 8604 N33 NRSCF

3
Argentine Central Bank Is Considering $5 Billion Repo Loan - Bloomberg

2018-08-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR HCS HSB 0005 8604 N33 UBS NRSCF HSEA HSEB HSBC ULSGF HBCYF

1
NMR / Nomura Holdings, Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-08-02 sec.gov
Form 6-K Table of Contents FORM 6-K &nb
NMR

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 65535H208